1,932 reports of this reaction
2.3% of all NINTEDANIB reports
#11 most reported adverse reaction
CONSTIPATION is the #11 most commonly reported adverse reaction for NINTEDANIB, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 1,932 FDA adverse event reports linking NINTEDANIB to CONSTIPATION. This represents approximately 2.3% of all 85,660 adverse event reports for this drug.
NINTEDANIB has an overall safety score of 85 out of 100. Patients taking NINTEDANIB who experience constipation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONSTIPATION is a less commonly reported adverse event for NINTEDANIB, but still significant enough to appear in the safety profile.
In addition to constipation, the following adverse reactions have been reported for NINTEDANIB:
The following drugs have also been linked to constipation in FDA adverse event reports:
CONSTIPATION has been reported as an adverse event in 1,932 FDA reports for NINTEDANIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONSTIPATION accounts for approximately 2.3% of all adverse event reports for NINTEDANIB, making it a notable side effect.
If you experience constipation while taking NINTEDANIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.